EGFR and lung cancer: in an observational, prospective, registry‐based study of The Thoracic Tumours Registry (TTR), that included 9239 Spanish patients diagnosed with lung cancer and other thoracic tumors (2016–2020), considered that national strategies are urgently needed to implement NGS in an integrated and cost‐effective way in lung cancer and analyzed the global testing of EGFR (67.0%), ALK (54.9%), and ROS1 (30.3%).23